HDAC inhibitor (SAHA) enhances B7-H3-specific CAR T cell cytotoxic efficacy against chondrosarcoma cells and prolongs survival in an orthotopic mouse model
Translational Oncology · 2025-12 · 62 · 102538
DOI: 10.1016/j.tranon.2025.102538 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Oncology, 2025-12. Verfasst von David O Osei-Hwedieh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA; Orthopaedic Oncol…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Department of Defense.
Abstract (Originalsprache)
High-grade Chondrosarcoma (Grades II, III, and dedifferentiated) is an aggressive primary malignant bone tumor characterized by hyaline cartilaginous neoplastic tissue without any effective systemic therapy. Localized disease is treated with a complete surgical resection with negative margins. However, high-grade chondrosarcoma often spreads systemically, leading to low overall survival rates of 29 %. These clinical findings emphasize the urgent need for improved systemic therapies. Among them is chimeric antigen receptor (CAR) T cell therapy. In this study, tumor-associated antigen B7-H3, which is highly expressed in chondrosarcoma cells but has a restricted expression in normal tissues, is targeted with B7-H3-specific CAR T cells. Our results show that these CAR T cells are effective in killing chondrosarcoma cells in vitro and retard chondrosarcoma tumor growth in immunodeficient mice, which resulted in prolonged survival of tumor-bearing mice. To enhance the antitumor activity of B7-H3 CAR T cells, tumor cells or CAR T cells were treated ex-vivo with a low dose of vorinostat (SAHA), a histone deacetylase (HDAC) inhibitor that upregulates B7-H3 transcription and expression in several types of solid cancer cells as well as the chimeric antigen receptor. Our results demonstrate that treatment of B7-H3 CAR T cells or chondrosarcoma cells with SAHA enhances CAR T cell antitumor cytotoxic activity in vitro and in vivo.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departments of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA; Orthopaedic Oncology Service, Massachusetts General Hospital, Harvard Medical School, 5…
- Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA; Department of Orthopaedic Surgery, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 9004…
- Departments of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA; Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Str…
Förderung
- U.S. Department of Defense
Zitieren
APA
Osei-Hwedieh, D. O., He, L., Wang, K., Fan, S., Ferrone, S., Wang, X., & Schwab, J. H. (2025). HDAC inhibitor (SAHA) enhances B7-H3-specific CAR T cell cytotoxic efficacy against chondrosarcoma cells and prolongs survival in an orthotopic mouse model. Translational Oncology, 62, 102538. https://doi.org/10.1016/j.tranon.2025.102538
Vancouver
Osei-Hwedieh DO, He L, Wang K, Fan S, Ferrone S, Wang X, et al. HDAC inhibitor (SAHA) enhances B7-H3-specific CAR T cell cytotoxic efficacy against chondrosarcoma cells and prolongs survival in an orthotopic mouse model. Translational Oncology. 2025;62:102538. doi:10.1016/j.tranon.2025.102538
BibTeX
@article{OseiHwedieh2025,
author = {Osei-Hwedieh, David O and He, Lile and Wang, Kun and Fan, Song and Ferrone, Soldano and Wang, Xinhui and Schwab, Joseph H},
title = {HDAC inhibitor (SAHA) enhances B7-H3-specific CAR T cell cytotoxic efficacy against chondrosarcoma cells and prolongs survival in an orthotopic mouse model},
journal = {Translational Oncology},
year = {2025},
volume = {62},
pages = {102538},
doi = {10.1016/j.tranon.2025.102538}
}
EUVIMED